Annals of Indian Academy of Neurology
: 2020  |  Volume : 23  |  Issue : 3  |  Page : 369--371

A case of genetically confirmed chorea-acanthocytosis: Brain [18F]FDG-PET and [18F]FP-CIT-PET findings

Jong-Mok Lee1, Chae Moon Hong2, Ho-Sung Ryu1,  
1 Department of Neurology, Kyungpook National University Hospital, Daegu, South Korea
2 Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, South Korea

Correspondence Address:
Dr. Ho-Sung Ryu
Department of Neurology, Kyungpook National University Hospital, 130, Dongduk-ro, Jung-gu, Daegu - 41944
South Korea

How to cite this article:
Lee JM, Hong CM, Ryu HS. A case of genetically confirmed chorea-acanthocytosis: Brain [18F]FDG-PET and [18F]FP-CIT-PET findings.Ann Indian Acad Neurol 2020;23:369-371

How to cite this URL:
Lee JM, Hong CM, Ryu HS. A case of genetically confirmed chorea-acanthocytosis: Brain [18F]FDG-PET and [18F]FP-CIT-PET findings. Ann Indian Acad Neurol [serial online] 2020 [cited 2020 Aug 6 ];23:369-371
Available from:

Full Text


Chorea-acanthocytosis (ChAc, OMIM #200150), a rare autosomal recessively inherited disorder, has been known to be the most core form of neuroacanthocytosis syndrome.[1] Neurological symptoms comprise chorea, dystonia, parkinsonism, tics, seizure, cognitive impairment, and psychiatric illness, rendered by the central nervous system involvement. These symptoms are mostly presented in early adulthood. In addition, it can accompany the involvement of systemic organs, namely, the peripheral nerve, muscle, liver, and heart.[1] ChAc can be an important differential diagnosis of progressive heredodegenerative illness.

A 47-year-old man presented with progressive involuntary movements for 9 years. Initially, tongue protrusion and neck forward flexion occurred intermittently. Subsequently, he complained of sudden trunk lateroflexion while walking and lying down. He could not maintain his job because of the gradually worsening severity and frequency of these involuntary movements. Although he was administered various medications for symptomatic treatment, the involuntary movements were not well-controlled. He had no remarkable past medical history or family history. At the time of admission to our hospital, he could not perform daily living activities without assistance. He could not vocalize words appropriately. He continuously opened his mouth and only swallowed soft food materials without orolingual movement in the lying position. Upon motor examination, parkinsonian symptoms including decreased eye blinking, decreased facial expression, and bradykinesia were observed. Muscle wasting with weakness (4+/5) and decreased deep tendon reflexes were also observed on four limbs.

Complete blood count, liver function test, random blood sugar, renal function test, thyroid function test, antinuclear antibody, serum ferritin, serum ceruloplasmin, VDRL, HIV, chest X-ray radiography, and electrocardiography were normal. Peripheral blood smear examination showed 25% of acanthocytes [Figure 1] and the serum creatine kinase level (CK, 1382 U/L, normal range 39–308 U/L) was increased. Results of nerve conduction study and electromyography showed mainly peripheral neuropathy combined with myopathy. Brain magnetic resonance imaging (MRI) showed atrophy of bilateral putamen and caudate nuclei [Figure 2]a. The results of [18 F]fludeoxyglucose (FDG)-positron emission tomography (PET), [18 F]F-N-(3-fluoropropyl)-2β-carboxy methoxy-3β-(4-iodophenyl) nortropane (FP-CIT)-PET, and early perfusion image of [18 F]FP-CIT-PET are described in [Figure 2]b, [Figure 2]c, [Figure 2]d.{Figure 1}{Figure 2}

Whole exome sequencing (WES) revealed pathogenic compound heterozygote variants in the VPS13A gene resulting in premature truncation. The allele c.4411C>T (p. Arg1471Ter, NM_033305.3) was found, which has been reported previously.[2] A novel deletion variant, c.7736_7739del (p. Arg2579AsnfsTer26), shared by the patient's mother, not listed in the LVOD (, was detected. Both variants were assessed as pathogenic according to the 2015 American College of Medical Genetics and Association for Molecular Pathology guideline and were confirmed by the Sanger sequence.

We could diagnose this patient as ChAc successfully by means of WES, which has been known to be a strong tool to differentiate the diagnosis among various neurologic disorders. A novel mutation of the other allele, c.7736_7739del (p. Arg2579AsnfsTer26), also results in premature truncation. This variant was also found in the patient's mother as a single heterozygote, which warrants the loss of function in the VPS13A gene and that the pathogenic variants of this patient are trans-compound heterozygous.

Lack of functional chorein is the molecular basis of ChAc. Chorein is expressed ubiquitously but is highly expressed in the brain, testis, kidney, and spleen. It has been reported that chorein is located in the terminal of neurites in rat PC12 cells and is involved in dopamine release and exocytosis of dense-core vesicles, which is associated with involuntary movements of the limbs.[3] Many explanations, including altered Lyn kinase activity, the composition of the junctional complexes involved in anchoring the membrane to the cytoskeleton, or decreased protein level of β-adducin, have been proposed in attempt to understand the dysmorphic features of the erythrocyte membrane regarding the acanthocytosis.[3],[4] Chorein also participates in the regulation of diverse functions, including cytoskeletal architecture, exocytosis, and cell survival.[5]

The brain MRI appears generally similar to that of Huntington's disease [Figure 2]a. Recently, functional neuroimaging has been widely used, but the role of a differential diagnosis of ChAc has not been elucidated due to limited reports. The previous reports have shown that patients with chorea demonstrated progressive glucose hypometabolism in the striatum on [18 F]FDG-PET.[6] Our case demonstrated marked hypometabolism at both putamen and caudate nuclei, which suggests the postsynaptic neuronal loss of the striatum in this patient. In addition, mild hypometabolism in the frontal lobe was also observed in this case, as in the previous report.[7] These findings represent functional connectivity of the frontostriatal circuit, which is usually involved in other neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

Only a few cases of ChAc with presynaptic dopamine neurons were evaluated. It seems that dopamine neuronal functions are related to the duration of symptoms, and a shift of clinical phenotypes from hyperkinetic syndrome to parkinsonism in ChAc after a disease course of more than 10 years.[8] One ChAc patient with 6 years of disease duration revealed normal presynaptic dopamine neuronal function on [18 F]F-DOPA-PET.[9] The monozygotic twins with 4 years of disease course underwent [123 I]-β-CIT-SPECT and one of them showed asymmetricity in the striatum, but dopamine transporter (DAT) binding of the striatum was within normal limit.[10] The two patients, with a 20- and 17-year disease course, demonstrated decreased DAT binding using [123 I]-FP-CIT-SPECT.[8] In this case, the patient suffered for 9 years and showed mildly decreased but relatively preservation of presynaptic dopamine neuron at striatum. Interestingly, perfusion images, acquired for the first 5 min after intravenous injection of [18 F]FP-CIT, showed preserved blood flow at both the putamen and mildly decreased blood flow at both caudate nuclei. This perfusion/metabolism mismatch at striatum maybe associated with perfusion demand of relatively preserved presynaptic neurons.

In conclusion, functional images using PET suggest that the loss of postsynaptic neurons combined with relatively preserved presynaptic neurons. And degree of presynaptic neuronal loss may be associated with duration and severity of symptoms in patients with genetically confirmed ChAc. We expect that these findings could provide useful information on understanding the clinical features in patients with ChAc.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Walker RH. Untangling the thorns: Advances in the neuroacanthocytosis syndromes. J Mov Disord 2015;8:41-54.
2Dobson-Stone C, Danek A, Rampoldi L, Hardie RJ, Chalmers RM, Wood NW, et al. Mutational spectrum of the chac gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002;10:773-81.
3Velayos Baeza A, Dobson-Stone C, Rampoldi L, Bader B, Walker RH, Danek A, et al. Chorea-acanthocytosis. Genereviews. Available from: [Last accessed on 2002 Jun 14].
4Shiokawa N, Nakamura M, Sameshima M, Deguchi A, Hayashi T, Sasaki N, et al. Chorein, the protein responsible for chorea-acanthocytosis, interacts with beta-adducin and beta-actin. Biochem Biophys Res Commun 2013;441:96-101.
5Lang F, Pelzl L, Schols L, Hermann A, Foller M, Schaffer TE, et al. Neurons, erythrocytes and beyond -the diverse functions of chorein. Neurosignals 2017;25:117-26.
6Ehrlich DJ, Walker RH. Functional neuroimaging and chorea: A systematic review. J Clin Mov Disord 2017;4:8.
7Saiki S, Hirose G, Sakai K, Matsunari I, Higashi K, Saiki M, et al. Chorea-acanthocytosis associated with tourettism. Mov Disord 2004;19:833-6.
8Nagy A, Noyce A, Velayos-Baeza A, Lees AJ, Warner TT, Ling H. Late emergence of parkinsonian phenotype and abnormal dopamine transporter scan in chorea-acanthocytosis. Mov Disord Clin Pract 2015;2:182-6.
9Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Fukumura T, et al. Cerebral glucose metabolism and striatal 18f-dopa uptake by pet in cases of chorea with or without dementia. J Neurol Sci 1993;115:153-7.
10Muller-Vahl KR, Berding G, Emrich HM, Peschel T. Chorea-acanthocytosis in monozygotic twins: Clinical findings and neuropathological changes as detected by diffusion tensor imaging, fdg-pet and i-123-beta-cit-spect. J Neurol 2007;254:1081-8.